Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease

2004 ◽  
Vol 19 (5) ◽  
pp. 571-579 ◽  
Author(s):  
W. Farid Abdo ◽  
Dani�lle De Jong ◽  
Jan C.M. Hendriks ◽  
Martin W.I.M. Horstink ◽  
Berry P.H. Kremer ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cerebrospinal Fluid ◽  
Multiple System Atrophy ◽  
Cerebrospinal Fluid Analysis ◽  
Fluid Analysis

Polyamine patterns in the cerebrospinal fluid of patients with Parkinson's disease and multiple system atrophy

2010 ◽  
Vol 411 (19-20) ◽  
pp. 1532-1535 ◽  
Author(s):  
Man-Jeong Paik ◽  
Young-Hwan Ahn ◽  
Phil Hyu Lee ◽  
Hyunseung Kang ◽  
Chan Bae Park ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cerebrospinal Fluid ◽  
Multiple System Atrophy

Cerebrospinal fluid proteomic patterns discriminate Parkinson's disease and multiple system atrophy

2012 ◽  
Vol 27 (7) ◽  
pp. 851-857 ◽  
Author(s):  
Noriko Ishigami ◽  
Takahiko Tokuda ◽  
Masaya Ikegawa ◽  
Mika Komori ◽  
Takashi Kasai ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cerebrospinal Fluid ◽  
Multiple System Atrophy

scholarly journals Cerebrospinal Fluid Biomarkers in Multiple System Atrophy Relative to Parkinson’s Disease: A Meta-Analysis

2021 ◽  
Vol 2021 ◽  
pp. 1-9
Author(s):  
Dan Xie ◽  
Ling Feng ◽  
Hongyan Huang ◽  
Quanzhen Zhao ◽  
Pingping Ning ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cerebrospinal Fluid ◽  
Multiple System Atrophy ◽  
Meta Analysis ◽  
Csf Biomarkers ◽  
Flt3 Ligand ◽  
Cerebrospinal Fluid Biomarkers ◽  
Mean Differences ◽  
T Tau

Objective. To investigate the differences of candidate cerebrospinal fluid (CSF) biomarkers associated with multiple system atrophy (MSA) and Parkinson’s disease (PD). Method. Here, a systematic review and meta-analysis were conducted on studies related to CSF biomarkers associated with MSA and PD obtained from PubMed, Web of Science, Embase, and Cochrane databases. Data were pooled where appropriate and used to calculate standardized mean differences (SMDs) with 95% confidence intervals (CI). Heterogeneity was assessed using the I 2 statistic while Egger’s test was used to test for existing publication bias. Results. MSA patients had higher CSF t-tau ( SMD = 0.41 , 95% CI: 0.10 to 0.72) and YKL-40 ( SMD = 0.63 , 95% CI 0.12 to1.15) as well as DJ-1 ( SMD = 1.05 , 95% CI 0.67 to 1.42) levels than PD patients, while CSF p-tau ( SMD = − 0.17 , 95% CI, -0.31 to -0.02) and Aβ-42 ( SMD = − 0.33 , 95% CI, -0.55 to -0.12) levels in MSA patients were lower than those in PD patients. There were no differences in CSF’s GFAP and Flt3 ligand levels in both MSA and PD patients. Conclusion. The study revealed the differences in CSF biomarker levels between MSA and PD cohorts that can be further explored to clinically distinguish MSA from PD.

Sign in / Sign up

Export Citation Format

Share Document